ArticleJournal of the American Heart Association2025
Novel and Highly Potent Therapeutic Agent, Trametes Robiniophila Murr (Huaier), Mitigates Pulmonary Vascular Remodeling in Rodents.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) is a critical disease causing right ventricular failure and early death. Conventional single-pathway treatments are inadequate, highlighting the need for new therapies. Trametes robiniophila Murr (Huaier), a traditional Chinese medicine, inhibits cancer cell proliferation. Importantly, the aberrant proliferation of pulmonary artery smooth muscle cells (PASMCs) is a key contributor to increased pulmonary vascular resistance in PH. However, it remains unknown whether Huaier could protect against PH. This study aimed to examine whether Huaier could protect against PH as well as its underlying mechanisms.
methodsHuaier treatment effectively mitigated hypoxia- and monocrotaline-induced PH in rodent models, as evidenced by reductions in pulmonary artery pressure, right ventricular hypertrophy, and vascular remodeling. Transcriptomic and network pharmacology analyses suggested that Huaier effectively alleviates PH primarily through inhibiting the phenotypic switching of PASMCs.
resultsIn vitro, Huaier suppressed PASMCs proliferation and migration in both PDGF (platelet-derived growth factor)-treated PASMCs and PH-PASMCs. Mechanistically, Huaier treatment was found to significantly inhibit the Hif1α (hypoxia-inducible factor 1-alpha) signaling pathway, thereby reducing excessive lactate accumulation and abnormal glycolysis, and the NF-κB (nuclear factor κB) signaling pathway, thereby diminishing inflammatory responses. Additionally, Huaier activated the Nrf2 (nuclear factor erythroid 2-related factor 2) signaling pathway, enhancing mitochondrial function and alleviating oxidative stress. The multifunctional roles of Huaier contributed to its inhibited effect on PASMCs proliferation and thus improved vascular remodeling.
conclusionsHuaier exerts multitarget therapeutic effects against PH by concurrently modulating metabolic reprogramming, inflammation and oxidative homeostasis, thereby inhibiting PASMCs-driven vascular remodeling. These findings position Huaier as a promising candidate for PH treatment, warranting further clinical trials to validate its translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.